These innovative agents represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. Trizepatide, https://violasonp916540.bloggadores.com/38040566/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide